Enveric Biosciences Advances EB-003 for Mental Health Disorders, Eyes 2025 IND Filing
Key Insights
Enveric Biosciences (search) is progressing EB-003, a neuroplastogenic molecule, for treating mental health disorders (search) without hallucinogenic effects.
Preclinical data confirms EB-003's oral bioavailability and brain penetration, targeting serotonergic receptors (search) with minimal off-target interactions.
Enveric plans to submit an Investigational New Drug (IND) application to the FDA for EB-003 in the second half of 2025.
Enveric Biosciences (search) is making strides in the development of EB-003, a novel neuroplastogenic molecule designed to address difficult-to-treat mental health disorders (search). The company aims to offer a therapeutic option without the hallucinogenic effects commonly associated with DMT and related analogs. With promising preclinical data and a strategic focus on neuropsychiatric indications, Enveric Biosciences is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration (FDA) in the second half of 2025.
EB-003: A Novel Approach to Mental Health Treatment
According to Joseph Tucker, Ph.D., director and CEO of Enveric, EB-003 has shown significant promise in preclinical studies. Data indicates that the molecule can be administered orally and effectively penetrate the brain, reaching levels expected to produce the desired therapeutic effects. Furthermore, preclinical safety and pharmacology studies have confirmed that EB-003 selectively targets desired serotonergic receptors (search) while minimizing potentially harmful off-target interactions, a common issue with serotonin-like drugs. This selectivity is a key differentiator, potentially enhancing the drug's value and safety profile.
Preclinical Findings Support Clinical Development
The company's research has demonstrated EB-003's oral bioavailability and significant brain exposure in preclinical models. These findings support the expedited development of the drug, with the anticipation of dosing the first patient in 2025. Additional positive results from preclinical safety and pharmacology studies have confirmed the drug's selective activity with desired serotonergic neuroreceptors and its ability to minimize potential adverse cardiovascular and CNS events.
Financial Status and Future Outlook
Enveric Biosciences (search) reported a net loss attributable to stockholders of $2.1 million for the third quarter of 2024, which included $500,000 in net non-cash expenses. This compares favorably to a net loss of $2.8 million for the same period in 2023. Total operating expenses were $2.08 million, down from $3.45 million in the previous year. As of September 30, 2024, the company had $3.1 million in cash on hand and an accumulated deficit of $102.92 million. The company acknowledges the need to raise additional capital to continue as a going concern, as detailed in their SEC filing.
Additional Corporate Highlights
Beyond EB-003, Enveric Biosciences (search) has strengthened its intellectual property estate for the EVM301 portfolio, securing five additional U.S. patents. The company has also entered into a licensing agreement with Aries Science & Technology to clinically develop and market Enveric's patented product for radiation dermatitis (search).